TMCnet News
Genocea Announces Upcoming Presentations at SITC 2018Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the titles and times of its presentations at the upcoming 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2018) taking place November 7 to 11, 2018 at the Walter E. Washington Convention Center in Washington, D.C. The following posters will be located in Poster Hall E. While the Poster Hall will be opn on Friday, November 9 from 8 a.m. – 8 p.m. and Saturday, November 10 from 8 a.m. – 8:30 p.m., the three Genocea posters will be presented simultaneously on Saturday, November 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m. Poster Number: P154 Poster Number: P166 Poster Number: P174 Per SITC policy, full abstracts are embargoed until 8 am ET on November 6, 2018. About Genocea Biosciences, Inc. Contact: |